Relief Therapeutics News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

18.09.24	Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 (EQS Group)
02.09.24	Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 (EQS Group)
26.04.24	RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting (EQS Group)
01.09.23	Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (EQS Group)
19.07.23	Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health (EQS Group)
15.05.23	Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory (EQS Group)
03.05.23	Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares (EQS Group)
28.04.23	Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders (EQS Group)
16.03.23	Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe (EQS Group)
28.02.23	Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars (EQS Group)
20.12.22	Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements (PR Newswire)
14.12.22	Relief Therapeutics to Participate in January Investor Meetings (EQS Group)
21.11.22	APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival (PR Newswire)
21.11.22	APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival (EQS Group)
12.09.22	Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum (EQS Group)
07.09.22	Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (EQS Group)
09.05.22	Relief Therapeutics to Participate in Industry and Investor Conferences in May (EQS Group)
02.02.22	EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock (EQS Group)
12.01.22	NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics (PR Newswire)
05.01.22	EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January (EQS Group)
06.07.21	NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia (PR Newswire)
06.08.20	FDA erteilt IND-Zulassung zur Behandlung mittelschwer bis schwer an COVID-19 erkrankter Patienten mit RLF-100 (Aviptadil), um ein Fortschreiten der Erkrankung bis zum Lungenversagen zu verhindern (Businesswire)
06.08.20	FDA Grants Inhaled Use IND for RLF-100 (Aviptadil) to Treat Patients With Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure (Businesswire)
04.08.20	Klinische Studie mit RLF-100 (Aviptadil) zeigte rasche Erholung von Lungenversagen und Hemmung der Replikation von Coronaviren in menschlichen Lungenzellen (Businesswire)
03.08.20	RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells (Businesswire)
29.07.20	FDA gewährt erweitertes Zugangsprotokoll für RLF-100 (Aviptadil) bei Atemversagen durch COVID-19 (Businesswire)
29.07.20	FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19 (Businesswire)
16.07.20	NeuroRx und Relief Therapeutics geben den Beschluss des Datenüberwachungskomitees bekannt, die Phase 2/3-Studie von RLF-100 bei schwerer COVID-19-Erkrankung fortzusetzen (Businesswire)
16.07.20	NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19 (Businesswire)
24.06.20	NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19 (Businesswire)
11.06.20	Relief Therapeutics und NeuroRx erweitern klinische Studie zur Prüfung von RLF-100 bei schwerkranken COVID-19-Patienten mit respiratorischer Insuffizienz um das Houston Methodist Hospital (Businesswire)
11.06.20	Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients With Respiratory Failure to Houston Methodist Hospital (Businesswire)
08.06.20	Relief Therapeutics und NeuroRx erweitern die klinische RLF-100-Studie auf alle Patienten mit schwerem COVID-19-Verlauf und Lungenversagen (Businesswire)
02.06.20	Relief Therapeutics und NeuroRx melden Aufnahme der ersten Teilnehmer zur Erprobung von RLF-100 in klinischer Phase 2b/3-Studie bei Patienten mit akuter Atemnot aufgrund von COVID-19 (Businesswire)
02.06.20	Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress (Businesswire)
06.05.20	Relief Therapeutics Holding (RLF:SIX) Drug Aviptadil Enters FDA Trial at NYU Langone Health, New York, to Treat COVID-19-Induced Acute Respiratory Distress (Businesswire)
09.04.20	Aviptadil von Relief Therapeutics (RLF:SIX) wird am Thomas Jefferson University Hospital in Philadelphia im Rahmen einer FDA-Studie zur Behandlung der COVID-19-induzierten akuten Atemnot getestet (Businesswire)
09.04.20	Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at Thomas Jefferson University Hospital in Philadelphia, to Treat COVID-19-induced Acute Respiratory Distress (Businesswire)
07.04.20	Relief Therapeutics (RLF:SIX) startet FDA-Studie mit Aviptadil an der University of Miami zur Behandlung von COVID-19-induzierter Atemnot (Businesswire)
07.04.20	Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress (Businesswire)
02.04.20	RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA (Businesswire)
17.03.20	RELIEF THERAPEUTICS HOLDING SA (SIX: RLF) kündigt Pläne an, Aviptadil zur Behandlung des akuten Atemnotsyndroms (ARDS) bei Patienten mit COVID-19-Infektion zu testen (Businesswire)
17.03.20	RELIEF THERAPEUTICS HOLDING SA (SIX: RLF) Announces Plans to Test Aviptadil for the Treatment of COVID-induced Acute Respiratory Distress Syndrome (ARDS) (Businesswire)
11.03.20	RELIEF THERAPEUTICS Holding SA (SIX: RLF) nominiert Prof. Dr. Jonathan Javitt, MD, MPH, für die Wahl zum Vizepräsidenten des Verwaltungsrates auf der bevorstehenden Generalversammlung (Businesswire)
11.03.20	RELIEF THERAPEUTICS Holding SA (SIX: RLF) announces the proposal of Prof. Jonathan Javitt, M.D., M.P.H., at the upcoming general assembly as Vice Chairman of the Board (Businesswire)
12.08.19	RELIEF THERAPEUTICS Holding SA Announces Divestment of its Subsidiary Relief Therapeutics SA to Sonnet BioTherapeutics, Inc. to Ensure the Development of Atexakin Alpha (Interleukin-6) (Businesswire)
13.09.18	RELIEF THERAPEUTICS Holding SA trifft Auslizenzierungsvereinbarung mit der H&H Group (Businesswire)
13.09.18	RELIEF THERAPEUTICS Holding SA Announces an Out-Licensing Agreement with H&H Group (Businesswire)
25.10.16	Relief Therapeutics Holding AG und FirstString Research Inc. kündigen strategische Zusammenarbeit bei der Entwicklung von Atexakin Alfa an (Businesswire)
25.10.16	Relief Therapeutics Holding AG and FirstString Research Inc. Announce a Strategic Collaboration for the Development of Atexakin Alfa (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.56	1.73 %	K V
CieFinRichemont	123.20	1.69 %	K V
Logitech Intl	72.74	0.75 %	K V
Lonza Grp	529.20	0.49 %	K V
Kuehne+Nagel Int	209.80	0.48 %	K V
ABB	49.66	-0.60 %	K V
Sika	229.80	-0.61 %	K V
Geberit	522.40	-0.72 %	K V
Holcim	88.90	-0.98 %	K V
UBS Group	27.99	-1.27 %	K V

mehr

02.09.24		Relief Therapeutics-Aktie gewinnt: PKU GOLIKE könnte Phenylalaninspiegel im Blut senken
30.08.24		Relief Therapeutics-Aktie im Plus: Deutlich weniger Verlust im Halbjahr
05.08.24		Relief Therapeutics-Aktie im Minus: Übernahme Lizenzgebühren
27.06.24		Relief Therapeutics-Aktie höher: Aktionäre verweigern Décharge
08.05.24		Relief Therapeutics-Valoren gewinnen: Relief Therapeutics baut Führungsteam um
30.04.24		Relief Therapeutics-Aktie tiefer: Relief Therapeutics rutscht wegen Abschreiber tiefer ins Minus
22.03.24		Relief Therapeutics vereinbart US-Lizenz und Lieferabkommen mit Eton Pharma - Aktie springt hoch
28.02.24		Relief Therapeutics sichert sich Kapitalzusage über 50 Mio Fr. - Aktie fester